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Abstract Hepatitis E virus (HEV) infection has emerged
as a global health issue, but no approved medication is
available. The nucleoside analogue 2’-C-methylcytidine
(2CMC), a viral polymerase inhibitor, has been shown to
inhibit infection with a variety of viruses, including hep-
atitis C virus (HCV). Here, we report that 2CMC signifi-
cantly inhibits the replication of HEV in a subgenomic
replication model and in a system using a full-length
infectious virus. Importantly, long-term treatment with
2CMC did not result in a loss of antiviral potency, indi-
cating a high barrier to drug resistance development.
However, the combination of 2CMC with ribavirin, an off-
label treatment for HEV, exerts antagonistic effects. Our
results indicate that 2CMC serves as a potential antiviral
drug against HEV infection.
Introduction
Hepatitis E virus (HEV) is a single-stranded, positive-sense
RNA virus, and its genome contains three open reading
frames (ORFs). ORF1 encodes a polyprotein that serves as
a precursor of all of the nonstructural proteins needed for
HEV replication. ORF2 encodes the capsid protein of the
HEV virion. ORF3 encodes a small multifunctional protein
with a molecular mass of 13 kDa [11]. HEV was initially
thought to cause acute infection only in developing
countries. However, over the last decade, hepatitis E cases
have frequently been reported in developed countries and
have been recognized mainly as autochthonous cases rather
than an imported disease [11, 12]. Generally, HEV infec-
tion is self-limiting and asymptomatic, and as a conse-
quence, its mortality rate is low. However, it can cause
high mortality in pregnant women. In immunocompro-
mised patients receiving organ transplantation, more than
60% of HEV-infected patients develop chronic disease and
quickly progress towards severe liver complications such
as fibrosis and cirrhosis [20]. In addition to hepatitis, this
virus has been associated with a broad range of extrahep-
atic manifestations, in particular, renal and neurological
injuries [14, 21]. Therefore, the development of specific
antiviral drugs for HEV infection is urgently required.
Nucleoside analogues have been used clinically for
almost 50 years and represent the cornerstones for treat-
ment of patients with cancer or viral infection. Ribavirin
(RBV) has been used as an off-label antiviral drug,
showing high efficacy in many chronic HEV patients, but
HEV mutations associated with ribavirin treatment failure
have been reported [4, 7]. Sofosbuvir (SOF), a potent
direct-acting agent (DAA) against hepatitis C virus (HCV)
[2], has been recently suggested to inhibit HEV replication
in cell culture and exert an additive effect when combined
with ribavirin [4]. However, other in vitro and clinical
studies have demonstrated that sofosbuvir is not very
effective against HEV infection [8, 18, 19], suggesting that
this drug might not be a promising candidate for the
treatment of chronic HEV patients.
2’-C-methylcytidine (2CMC) was initially identified as
a competitive inhibitor of the HCV RNA-dependent RNA
polymerase (RdRp). In addition to HCV, it has been shown
to inhibit the replication of a variety of other viruses (e.g.,
dengue virus and norovirus) [13, 15]. It also has been
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reported to inhibit cutthroat trout virus, a non-pathogenic
fish virus that is remarkable similar to HEV [6]. In this
study, we have demonstrated that 2CMC efficiently inhibits
HEV replication and thus is a potential candidate for anti-
HEV drug development.
Materials and methods
Reagents and antibodies
2CMC, RBV, guanosine triphosphate (GTP) and cytidine
5’-triphosphate (CTP) were purchased from Sigma-Aldrich
and were dissolved in dimethyl sulfoxide (DMSO) (Sigma-
Aldrich, St Louis, MO). The HEV-specific antibody was
purchased from EMD Millipore (MAB8002).
HEV cell culture models
Multiple cell lines were employed in this study, including
human hepatoma cell lines (Huh7 and PLC/PRF/5), a
human embryonic kidney cell line (HEK293), a human
primary glioblastoma cell line (U87), and a human fetal
lung fibroblast cell line (MRC5). Huh7 and U87 cells were
kindly provided by Professor Bart Haagmans from the
Department of Viroscience, Erasmus Medical Center. The
human embryonic kidney 293 cell line, PLC/PRF/5 and
MRC5 were originally obtained from ATCC (http://www.
atcc.org). These cells were cultured in Dulbecco’s modified
Eagle medium (Lonza Biowhittaker, Verviers, Belgium)
supplemented with 10% fetal bovine serum, 100 IU of
penicillin per ml, and 100 lg of streptomycin per ml. For
the full-length HEV model, a plasmid construct containing
the full-length HEV genome (Kernow-C1 p6 clone; Gen-
Bank accession number JQ679013) was employed to
generate HEV genomic RNA using an Ambion mMessage
mMachine in vitro RNA transcription Kit (Thermo Fisher
Scientific Life Sciences) [16]. Huh7, PLC/PRF/5, HEK293,
U87 and MRC5 cells were electroporated with full-length
HEV genomic RNA to generate consecutive HEV-infected
cell models (Huh7-p6, PLC/PRF/5-p6, HEK293-p6, U87-
p6 and MRC5-p6). To generate the subgenomic (p6-Luc)
HEV model, a plasmid construct containing subgenomic
HEV was used. This plasmid has an HEV sequence in
which the 5’ portion of HEV ORF2 was replaced with the
in-frame Gaussia princeps luciferase reporter gene [16].
Huh7, U87 and HEK293 cells were electroporated with
HEV subgenomic RNA to generate HEV subgenomic
models (Huh7-p6-Luc, U87-p6-Luc, and HEK293-p6-
Luc). To normalize nonspecific effects of 2CMC on the
luciferase signal, Huh7 cells stably expressing a non-se-
creted firefly luciferase under the control of the human
phosphoglycerate kinase (PGK) promotor (PGK-Luc) were
used [18]. In addition, Huh7 cells harboring a subgenomic
HCV bicistronic replicon (I389/NS3-3 V/LucUbiNeo-ET)
(Huh7-HCV-Luc) were used as positive control of antiviral
activity.
Quantification of HEV replication
For Gaussia luciferase, the secreted luciferase activity in
the cell culture medium was measured using a BioLux
Gaussia Luciferase Flex Assay Kit (New England Biolabs).
Gaussia luciferase activity was quantified using a LumiStar
Optima luminescence counter (BMG LabTech, Offenburg,
Germany). For the full-length infectious models (HEV-p6),
intracellular viral RNA was quantified. RNA was isolated
using a Machery-Nucleo Spin RNA II kit (Bioke, Leiden,
The Netherlands) and quantified using a NanoDrop ND-
1000 spectrophotometer (Wilmington, DE, USA). cDNA
was prepared from total RNA using a cDNA Synthesis Kit
(Takara Bio Inc, USA). The HEV RNA level was quanti-
fied using a SYBR Green–based real-time PCR assay
(Applied Biosystems SYBR Green PCR Master Mix,
Life Technologies, CA, USA) according to the manufac-
turer’s instructions. The PCR steps consisted of a 10 min
holding stage (95 C) followed by 40 cycles of 15 s at
95 C, 30 s at 58 C, and 30 s at 72 C. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was used as a refer-
ence gene to normalize gene expression. Relative gene
expression was normalized to GAPDH using the
cFig. 1 2CMC exerts a potent anti-HEV effect. (A) Huh7-p6-Luc
cells and Huh7-HCV-Luc cells were treated with the indicated
concentrations of 2CMC for 24 h, 48 h, or 72 h, and the untreated
(CTR) group served as a control. Luciferase activity was measured at
the indicated time points. Data are the mean ± SEM of four
independent experiments. CTR, non-treatment control. *, P\ 0.05;
**, P\ 0.01; ***, P\ 0.001. (B) Huh7-p6-Luc cells were treated
with 10 lM 2CMC for 48 h. The 50% inhibitory concentration (IC50)
and 50% cytotoxic concentration (CC50) of 2CMC against HEV
replication were calculated using GraphPad Prism 5 software.
(C) Huh7-p6 cells were treated with the indicated concentrations of
2CMC for 48 h. RT-PCR analysis of HEV RNA and cell viability
analysis were performed. Data are the mean ± SEM of four
independent experiments. CTR, non-treatment control; Abs 490,
absorption at 490 nm; ***, P\ 0.001. (D) Immunoblot analysis of
the HEV ORF2 protein level in the Huh7-cell-based HEV infectious
cell model (Huh7-p6) treated with 2CMC (10 lM) for 48 h. Data are
the mean ± SEM of four independent experiments. CTR, non-
treatment control; *, P\ 0.05. (E) Hepatic and nonhepatic cells were
treated with indicated concentrations of 2CMC for 48 h. RT-PCR
analysis of HEV RNA was performed. Data are the mean ± SEM of
four independent experiments. CTR, non-treatment control.
(F) HEK293T-p6-luc and U87-p6-luc cells were treated with the
indicated concentrations of 2CMC for 48 h and then were subjected
to luciferase activity analysis. Data are the mean ± SEM of three
independent experiments. CTR, non-treatment control; *, P\ 0.05.
(G) The indicated cells were treated with 2CMC for 48 h and then
subjected to cell viability analysis using an MTT assay
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formula 2-DDCT (DDCT = DCTsample - DCTcontrol). The
HEV primer sequences were as follows: HEV-F, 5’-ATTG
GCCAGAAGTTGGTTTTCAC-3’; HEV-R, 5’-CCGTGG
CTATAATTGTGGTCT-3’; GAPDH-F, 5’-TGTCCCCAC
CCCCAATGTATC-3’; GAPDH-R, 5’CTCCGATGCCTG
CTTCACTACCTT-3’.
MTT assay
The cells were seeded in a 96-well plate, and 10 mM
3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bro-
mide (MTT) (Sigma) was added to the cells. Subsequently,
the cells were incubated at 37 C with 5% CO2 for 3 h. The
culture medium was then removed, and 100 ll of DMSO
was added to each well. The absorbance of each well was
read in a microplate absorbance reader (Bio-Rad, Japan) at
wavelength of 490 nm.
Long-term treatment assay
For the long-term treatment assay of the subgenomic model
(Huh7-p6-luc), the cells were seeded into a 96-well plate with
5000 cells per well. The cells of the CTR and 2CMC treatment
groups were passaged and seeded with the same number of
cells every 3 days (d), and cells incubated with vehicle (non-
treatment) or 2CMC (10 lM) were maintained throughout the
entire incubation period. For the long-term treatment assay of
infectious model (Huh7-p6), the cells were seeded into a
48-well plate with 2 9 104 cells per well. The cells of the CTR
or 2CMC treatment groups were passaged and seeded with the
same number of cells every 3 days, and cells incubated with
vehicle (non-treatment) or 2CMC (10 lM) were maintained
throughout the entire incubation period.
Western blot assay
Cultured cells were lysed in Laemmli sample buffer con-
taining 0.1 M DTT and heated for 5 min at 95 C, followed
by loading onto a 10% sodium dodecyl sulfate polyacry-
lamide gel and separation by electrophoresis for 90 min at
120 V, after which the proteins were electrophoretically
transferred onto a polyvinylidene difluoride membrane (In-
vitrogen) for 1.5 h with an electric current of 250 mA.
Subsequently, the membrane was blocked with a mixture of
2.5 ml of blocking buffer (Odyssey, USA) and 2.5 ml of
phosphate-buffered saline containing 0.05% Tween 20. This
was followed by overnight incubation with anti-HEV capsid
protein primary antibodies (1:1000) at 4 C. The membrane
was then washed three times, followed by incubation for 1 h
with goat anti-mouse IRDye-conjugated secondary antibody
(Li-COR Biosciences, Lincoln, USA) (1:5000). After
washing three times, protein bands were detected using an
Odyssey 3.0 Infrared Imaging System.
IC50 and CC50 calculation
The 50% inhibitory concentration (IC50) value and 50%
cytotoxic concentration (CC50) were calculated based on
the model YBottom þ (Top-Bottom)/ (1 þ 10^((LogIC50-
X)*HillSlope)) using GraphPad Prism 5 software (Graph-
Pad Prism 5; GraphPad Software Inc., La Jolla, CA, USA).
Statistical analysis
Statistical analysis was performed using the nonpaired,
nonparametric test with the Mann-Whitney test and one-way
ANOVA with Tukey’s multiple comparison post-test
(GraphPad Prism version 5.01; GraphPad Software). P-val-
ues less than 0.05 were considered statistically significant.
Results
In this study, the potential anti-HEV effect of 2CMC was
investigated in HEV replication models with concentra-
tions ranging from 0.1 lL to 10 lM. We demonstrated
that 2CMC significantly reduced HEV-driven luciferase
activity, and the anti-HEV activity was comparable with its
anti-HCV effect at the concentration of 10 lM (Fig. 1A).
The IC50 value of 2CMC against HEV replication was
1.64 lM, the CC50 of 2CMC in Huh7 cells was 111.2 lM,
and the selectivity index (SI, CC50/IC50) was 67.8
(Fig. 1B). The anti-HEV effect of 2CMC was further
confirmed in the full-length (Kernow-C1, p6) infectious
model of HEV genotype 3 by both RT-PCR assay
(Fig. 1C) and western blot assay (Fig. 1D).
Since HEV-related extrahepatic manifestations have been
reported [12], we extended our study to some other hepatic
and nonhepatic cell lines. HEV infectious or replication
models were established in HEK293, PLC/PRF/5, MRC5
and U87 cells. The anti-HEV potential of 2CMC in these
cell lines was tested. In line with the results observed in
Huh7-based HEV replication and infectious models, we
observed a similar anti-HEV effect of 2CMC in all these cell
models without affecting the cell viability (Fig. 1E to G).
Drug resistance is one of the main factors that limit the
effectiveness of antiviral treatment. To characterize 2CMC
in this respect, we performed experiments in which both
HEV replication and infectious models were constantly
exposed to 2CMC (10 lM). Interestingly, 2CMC retained
its anti-HEV activity in both models even after long-term
exposure (Fig. 2A and B). Furthermore, the negative con-
trol retained high levels of luciferase activity after long-
term incubation with 2CMC, excluding the loss of cell
viability during the experimental period (Fig. 2C). Taken
together, 2CMC displays a high barrier for drug resistance
development.
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Fig. 2 2CMC retains anti-HEV effect in Huh7-p6-luc and Huh7-p6
models after long-term treatment. (A) Treatment of 2CMC in the
Huh7-p6-luc model for 27 days. The cells were passaged every
3 days and were incubated with vehicle (non-treatment) or 2CMC
(10 lM) throughout the entire period. Data are the mean ± SEM of
four independent experiments. CTR, non-treatment control. (B) Treat-
ment of 2CMC in the Huh7-p6 model for 15 days. The cells were
passaged every 3 days and were incubated with vehicle (non-
treatment) or 2CMC (10 lM) throughout the entire period. Data are
the mean ± SEM of four independent experiments. (C) Treatment of
2CMC in the Huh7-p6-luc model for 27 days. The absolute luciferase
values of Huh7-p6-luc cells are shown at indicated time points
Fig. 3 Combination of CTP
and GTP with 2CMC in the
Huh7-p6-luc model (A) and the
Huh7-p6 model (B). The cells
were treated with 2CMC, CTP
or GTP, alone or in combination
for 72 h before measurement of
luciferase activity. Data are the
mean ± SEM of four to six
independent experiments. *,
P\ 0.05; **, P\ 0.01; ***,
P\ 0.001; ns, not significant
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Theoretically, nucleoside/nucleotide analogs can serve as
potential direct-acting antivirals because they bind to the
viral RNA polymerase active site to block viral replication.
To evaluate the inhibitory specificity of 2CMC against HEV
replication, we performed a competition assay employing
the substrate cytidine triphosphate (CTP) as an analogous
competitor of 2CMC. Our results indicated that CTP
reversed the inhibitory effects of 2CMC on HEV replication
activity in a dose-dependent manner. In contrast, guanosine
triphosphate (GTP) exerted no effect, implying the inhibi-
tory specificity of 2CMC against HEV replication (Fig. 3A
and B). Another nucleoside analogue, ribavirin, has been
used clinically as an off-label treatment for HEV infection.
Thus, its anti-HEV effect in combination with 2CMC was
tested. Interestingly, a moderate antagonistic effect
(-36.93 lM2 %) was observed, implying that they employ a
similar antiviral mechanism (Fig. 4A and B).
Discussion
A variety of nucleoside analogues have been widely used
to treat viral infections due to their potent antiviral effects
and high barrier to drug resistance development. Ribavirin,
an guanosine analogue, is the drug of choice for treating
most chronic HEV patients. However, treatment failure has
been observed in some cases. Sofosbuvir, a prodrug of a
uridine nucleoside analogue that is very effective against
HCV, has been investigated recently for its anti-HEV
potency. However, there has been debate regarding its
potency against HEV [9, 17]. 2CMC, a cytidine nucleoside
analogue, has been shown to inhibit infection with a variety
of viruses, including HCV and HIV [5]. In this study, we
have demonstrated that 2CMC potently inhibits HEV
replication in different cell models, albeit with slight dif-
ferences (Fig. 1A and C). A possible explanation is that
Fig. 4 2CMC antagonizes ribavirin in the Huh7-p6-luc model.
(A) Huh7-p6-Luc cells were treated with 2CMC and ribavirin, alone
or in combination, for 72 h before analysis of luciferase activity.
Untreated cells served as a control. (B) The combinatory effect of
2CMC and ribavirin on HEV replication was analyzed using the
mathematical model MacSynergy. The three-dimensional surface plot
represents the differences (within the 95% confidence interval)
between actual experimental effects and theoretical additive effects of
the combination at various concentrations of the two compounds.
Data are the mean ± SEM of three independent experiments
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these models recapitulate the different steps of the HEV
life cycle. The full-length infectious clone (Huh7-p6)
models the entire cycle of HEV infection, whereas the
subgenomic model (Huh7-p6-luc) only mimics viral
replication due to the lack of ORF2 and ORF3.
Encouragingly, the anti-HEV activity was comparable
with its anti-HCV effect at particular concentrations. More
importantly, in the long-term treatment experiment, 2CMC
displayed a high barrier to resistance development, and we
demonstrated that this was a specific anti-HEV effect and
not due to cytotoxicity. It has been suggested that after it is
absorbed by the cells, 2CMC is converted to its 50-
triphosphate form (2CMC-CTP), which serves as an active
molecule that competes with the natural substrate CTP.
Consistent with this, our results demonstrated that CTP but
not GTP reverses the anti-HEV effect of 2CMC, revealing
a potential mechanism of action of 2CMC against HEV.
Since ribavirin has been widely used to treat chronic
HEV patients, a combined therapy of ribavirin with 2CMC
might be envisaged. To test this, the combinatory effects of
both drugs were investigated. Unexpectedly, an antago-
nistic effect was observed. These findings are in agreement
with the earlier observation of the combinatory effects of
ribavirin and 2CMC on HCV and HIV [3].
Of note, the potential adverse effects of 2CMC should
be carefully evaluated in future studies. The clinical
applications of nucleoside analogues have been limited in
some cases due to off- target effects. Mitochondrial DNA
polymerase is an important unintended target for many
nucleoside analogues. It has been reported that a nucleoside
analogue containing a 2-C-methyl (2-CM) group can
reduce mitochondrial transcription and oxidative phos-
phorylation, resulting in dysfunction of cell metabolism
[1, 10]. Therefore, it is recommended that future anti-HEV
drug development efforts should focus on the design of
less-toxic agents based on the main chemical structure of
2CMC.
In conclusion, 2CMC exerts potent anti-HEV effects in
well-established cell culture models, and serves as a
potential backbone for anti-HEV drug design. To achieve
better efficacy and fewer side effects, future research is still
required for drug optimization based on the chemical
structure of 2CMC.
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